Investing $ 3000 In These 3 Stocks Could Make You A Fortune Over The Next Decade


It takes money to make money. Most people know the old saying is true. But it doesn’t necessarily take a lot of money to make a lot of money.

Even an initial investment of $ 3,000 can grow into a substantial sum over time. The trick is to find the right opportunities to invest in. Buying stocks has proven to be a great way to generate huge returns over the long term.

But which stocks are good candidates for making a lot of money without having a lot of money to invest? Investing $ 3000 in these three stocks could make you a fortune over the next decade.

Image source: Getty Images.

1. Fastly: leader on the edge

Here’s a number to keep in mind: 75%. This is the percentage of Internet applications that will be built by companies in the coming years instead of being bought, according to market researcher International Data Corporation. It’s also the percentage of data that IDC expects to be processed at the cloud edge (the point where corporate networks connect to the cloud) by 2022. One company is uniquely positioned to benefit from this arrangement – Quickly (NYSE: FSLY).

Rapidly provides a leading cloud platform for software developers that is secure, scalable, cost effective, and blazingly fast. Its technology has quickly become a favorite for many of the world’s most innovative internet companies, including Alphabet, Microsoft, Shopify, and Mou.

The company currently claims well less than 1% of an addressable market that is over $ 35 billion and continues to grow. But Fastly’s sales are growing at a compound annual growth rate of 45%. The growth of Fastly will be largely driven by the growth of its existing customers. It also plans to continue to launch new products and further penetrate international markets. The tech stock is expected to be a huge winner over the next 10 years as it further captures the rapidly growing advanced platform market.

2. Guardant Health: Harnessing the Power of DNA

Genetic research is transforming the way cancer is treated. It also transforms the way cancer is diagnosed. Liquid biopsies are tests that detect cancer by finding fragments of DNA from tumors in the blood. These tests have the potential to save lives by allowing early diagnosis of cancer. Guardian health (NASDAQ: GH) stands out as a clear leader in the liquid biopsy market.

Guardant Health sells two already hugely successful liquid biopsy products. Guardant360 was the first complete liquid biopsy to gain approval from the Food and Drug Administration. Used for genomic profiling of all types of solid tumors, it helps match patients with the most appropriate cancer treatment. GuardantOMNI helps drug manufacturers screen patients for clinical trials evaluating investigational cancer drugs.

The COVID-19 pandemic has caused Guardant Health’s growth to decline slightly, but the company’s long-term outlook remains bright. The estimated US market potential for Guardant360 is approximately $ 6 billion. There is a much larger addressable market of over $ 45 billion for Guardant Health’s LUNAR liquid biopsies, which are being evaluated in clinical studies for use in early cancer detection and monitoring for recurrence. cancer.

3. Novavax: a dark horse of the vaccine against the coronavirus

The U.S. government’s Operation Warp Speed ​​(OWS) initiative has primarily funded the COVID-19 vaccination programs of major drug makers. But a small biotech that could be a dark horse in the race to develop a coronavirus vaccine has landed $ 1.6 billion in funding from OWS. This biotechnology is Novavax (NASDAQ: NVAX).

Novavax recently launched a phase 2 study of its COVID-19 vaccine candidate, NVX-CoV2373. Some analysts called the investigational vaccine the best-in-class potential after the company reported results from phase 1 testing. Novavax hopes to release interim results from its advanced-stage NVX-CoV2373 study in the fourth quarter of 2020.

If NVX-CoV2373 gets regulatory approvals, it could be a key player in an estimated $ 20 billion global market for coronavirus vaccines. The company also plans to seek FDA approval for another promising candidate, the NanoFlu influenza vaccine, which could generate maximum annual sales of $ 1.7 billion if approved. These are huge opportunities for a biotech with a market capitalization of around $ 7 billion.


Please enter your comment!
Please enter your name here